Production of smallpox vaccine approved

November 2006
Pharmaceutical Technology Europe;Nov2006, Vol. 18 Issue 11, p14
Trade Publication
The article reports on the approval of the production facility of Bavarian Nordic AS in Kvistgard, Denmark by the Danish Medicines Agency. After the authorization, the company could start to operate as a large-scale commercial production of smallpox vaccine. On the other hand, the company developed Imvamune as an alternative to conventional smallpox vaccines.


Related Articles

  • Bavarian's Smallpox Vaccine Pact Worth Up To $1.6 Billion. Sheridan, Cormac // BioWorld International;6/6/2007, Vol. 12 Issue 23, p1 

    The article reports on the contract won by Bavarian Nordic A/S to supply a stockpile of next-generation safe smallpox vaccines to the U.S. Department of Health and Human Services. The pharmaceutical company is expected to earn a total of $1.6 billion from the contract. The vaccine produced by...

  • Battling Bioterror.  // Pharmaceutical Executive;Oct2004, Vol. 24 Issue 10, p21 

    Reports on a contract awarded by the United States government to Acambis and Bavarian Nordic to develop and produce a Modified Vaccinia Ankara smallpox vaccine. Value of the deal; Reduction of complications in the weaker version of the vaccine.

  • Bavarian Nordic: HHS contract boosts smallpox vaccine franchise.  // PharmaWatch: Monthly Review;Jun2007, Vol. 6 Issue 6, p23 

    The article reports on the U.S. government supply contract earned by Bavarian Nordic for its smallpox vaccine Imvamune. It is stated that the U.S. department of Health and Human Services has informed Bavarian Nordic of its plan to purchase 20 million doses of Imvamune under the BioShield...

  • OTHER NEWS TO NOTE.  // BioWorld International;11/26/2008, Vol. 13 Issue 48, p2 

    This section offers news briefs on the biotechnology industries. Asterand plc has completed a placement of 4.3 million shares at 15 pence each. Bavarian Nordic A/S received a $25 million milestone payment from the U.S. government by submitting safety data from a Phase II trial of smallpox...

  • GOVERNMENT OF CANADA PROCURES IMVAMUNE SMALLPOX VACCINE.  // Worldwide Biotech;Jan2009, Vol. 21 Issue 1, p6 

    The article reports on the contract awarded by Public Works and Government Services Canada to Bavarian Nordic in January 2009 for the delivery of Imvamune, a Modified Vaccinia Ankara (MVA)-based, third generation smallpox vaccine. As stated, the procurement will be used by the Canadian...

  • OTHER NEWS TO NOTE.  // BioWorld Today;8/26/2009, Vol. 20 Issue 164, p5 

    This section offers news briefs on the pharmaceutical industry as of August 2009. Bavarian Nordic AS of Denmark is in negotiation with the government of the U.S. to develop a freeze-dried version of its small pox vaccine Imvamune. Cellceutix Corp. of Massachusetts has acquired rights to the...

  • Bavarian Nordic Stock Falls on Plans to Raise $50M for Vaccine. Sheridan, Cormac // BioWorld International;12/2/2009, Vol. 14 Issue 48, p1 

    This article reports on a decline in the value of stocks of Bavarian Nordic A/S in November 2009 as the company plans to raise funds to finance the development of its Imvamune next-generation smallpox vaccine. The Danish company's stocks fell more than three percent. The vaccine can be used by...

  • Bavarian Nordic Rises On First Vaccine Approval. Sheridan, Cormac // BioWorld International;8/14/2013, Vol. 18 Issue 33, p5 

    The article reports on the 6.6% increase in pharmaceutical company Bavarian Nordic A/S shares. It notes that this increase resulted from European Commission's approval of Bavarian Nordic's third-generation smallpox vaccine Imnavex which is based on a modified vaccinia Ankara (MVA) vector. The...

  • Bavarian Nordic shares rise on collaboration deal with GSK.  // PharmaWatch: Biotechnology;September 2004, Vol. 3 Issue 9, p18 

    Reports on the collaboration between Bavarian Nordic and GlaxoSmithKline on the production and marketing of Bavarian's smallpox vaccine Imvamue. Terms of the collaborative contract; Responsibility of Bavarian for development and production of Imvamune to the U.S. government under the National...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics